U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3Cl.Gd.6H2O
Molecular Weight 371.7
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GADOLINIUM CHLORIDE HEXAHYDRATE

SMILES

O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Gd+3]

InChI

InChIKey=PNYPSKHTTCTAMD-UHFFFAOYSA-K
InChI=1S/3ClH.Gd.6H2O/h3*1H;;6*1H2/q;;;+3;;;;;;/p-3

HIDE SMILES / InChI

Molecular Formula Gd
Molecular Weight 157.25
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cl
Molecular Weight 35.453
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/

Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA that is used in patients undergoing diagnostic contrast-enhanced MRI for visualization of pathological lesions in the CNS and all other body regions or for contrast-enhanced magnetic resonance angiography (MRA) to evaluate perfusion and flow-related abnormalities. It is a non-ionic, paramagnetic complex consisting of gadolinium (Gd3+) chelated with the macrocyclic compound dihydroxy-hydroxymethylpropyl-tetraazacyclododecane-triacetic acid (butrol). Gadavist (the trade name of gadobutrol) was approved by FDA in 2011 for intravenous use in diagnostic MRI in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. Application of gadobutrol in humans, up to a dose of 0.5 mmol/kg was shown to be well tolerated. Following intravenous administration, gadobutrol may increase MRI sensitivity for the detection of tumors and inflammatory and demyelinating diseases of the central nervous system which are associated with areas with blood-brain barrier defects due to altered perfusion or an enlarged extracellular space. Gadobutrol is not metabolized. It is eliminated in an unchanged form via the kidneys; extra-renal elimination is negligible. Side effects include headache, nausea, abnormal taste and feeling hot.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27169
Gene ID: 5444.0
Gene Symbol: PON1
Target Organism: Homo sapiens (Human)
105.0 mM [Ki]
Target ID: P52209
Gene ID: 5226.0
Gene Symbol: PGD
Target Organism: Homo sapiens (Human)
73.0 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DOTAREM

Approved Use

Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Launch Date

1.36373758E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
PubMed

PubMed

TitleDatePubMed
Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism.
1994 Sep
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors.
1997 May
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.
2001 Feb 9
Gadolinium-containing contrast media for radiographic examinations: a position paper.
2002 Oct
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium.
2004 May
Renal safety of gadolinium-based contrast agent for ionizing radiation imaging.
2006 Jul
Loss of primary cilia results in deregulated and unabated apical calcium entry in ARPKD collecting duct cells.
2006 Jun
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data.
2007 Aug
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008 Jul
Gadolinium and kidney disease: are your patients at risk?
2008 Mar-Apr
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency.
2009 Dec
Large sample of nephrogenic systemic fibrosis cases from a single institution.
2009 Oct
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture.
2010 Mar
Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
2010 Nov
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
2011 Feb 18
Heavy metal cations permeate the TRPV6 epithelial cation channel.
2011 Jan
Toxicological safety evaluation of gadobutrol.
2012 Nov
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
2016 Mar
Patents

Sample Use Guides

For adult and pediatric patients (2 years and older), the recommended dose of DOTAREM (gadoterate meglumine) is 0.2 mL/kg (0.1 mmol/kg) body weight administered as an intravenous bolus injection, manually or by power injector, at a flow rate of approximately 2 mL/second for adults and 1-2 mL/second for pediatric patients.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Thu Jul 06 04:20:48 UTC 2023
Edited
by admin
on Thu Jul 06 04:20:48 UTC 2023
Record UNII
261EX557HI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GADOLINIUM CHLORIDE HEXAHYDRATE
Systematic Name English
GADOLINIUM(III) CHLORIDE HEXAHYDRATE
Systematic Name English
GADOLINIUM TRICHLORIDE HEXAHYDRATE
Systematic Name English
GADOLINIUM CHLORIDE (GDCL3), HEXAHYDRATE
Common Name English
Code System Code Type Description
CAS
13450-84-5
Created by admin on Thu Jul 06 04:20:48 UTC 2023 , Edited by admin on Thu Jul 06 04:20:48 UTC 2023
PRIMARY
FDA UNII
261EX557HI
Created by admin on Thu Jul 06 04:20:48 UTC 2023 , Edited by admin on Thu Jul 06 04:20:48 UTC 2023
PRIMARY
PUBCHEM
197915
Created by admin on Thu Jul 06 04:20:48 UTC 2023 , Edited by admin on Thu Jul 06 04:20:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID80928637
Created by admin on Thu Jul 06 04:20:48 UTC 2023 , Edited by admin on Thu Jul 06 04:20:48 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY